Methicillin-resistant Staphylococcus aureus was initially detected in Europe in the 1960s, soon after the introduction of methicillin. Naturally-resistant strains were isolated in some countries before the use of methicillin or related agents. These strains probably spread initially from one or more ancestral genetic clones in natural populations of S. aureus by horizontal transfer and recombination. These original strains, possibly emerging in many countries, then increased in numbers and diversity in hospitals as a result of selection by exposure to antibiotics and by crossinfection. After a decline in the 1970s, new epidemic strains that differed from the original MRSAs emerged in Australia, the United States, and the Irish Republic and have now reached global proportions. Most strains are highly resistant to antibiotics and some are only sensitive to vancomycin or teicoplanin. Intercountry and intercontinental spread has also occurred by transfer of infected or colonized patients or staff. However, the main mode of spread is person-to-person within a unit or hospital and subsequently to other hospitals in the same country. New epidemic strains have continued to emerge and decline for unknown reasons. On the basis of evidence from countries where MRSA is not a problem, it has been suggested that early detection, effective infection control measures, and rational antibiotic use will limit the transmission of these organisms; however, spread is still increasing in many countries.
the next 10 years, increasing numbers of isolates and outbreaks were reported, mainly in European countries (e.g., the United Kingdom [5, 6] , Denmark [7] , France [8] , and Switzerland [9] ) and occasionally, elsewhere (e.g., Australia [10] ). There were also reports of S. aureus isolates with naturally acquired resistance in countries (e.g., in Poland [11] , Turkey [12] and India [13] ) where methicillin or other penicillinase-resistant penicillins
were not yet available. Although MRSA was reported in the United States in the early 1960s, the first important outbreak was not reported until 1968 [14] , and major interhospital spread apparently did not occur for another 5-10 years.
The initial MRSA isolates were resistant to multiple drugs including penicillin, tetracycline, and usually, streptomycin. Some strains were resistant to erythromycin, lincomycin, neomycin, kanamycin, and novobiocin. They belonged predominately to phage group III, with similar phage patterns in different countries (table 1) . Mixed phage groups I (usually phage type 29) and III strains later appeared in South Africa, Switzerland, and the United Kingdom. Table 2 shows the results of prevalence surveys performed in a large general hospital in Birmingham, England in 1970 and 1979 -1980 and indicates the variation in phage types and antibiotic resistance patterns. Interhospital spread occurred but was usually less frequent than that described in reports of the 1980s and 1990s.
The emergence of similar strains with resistance to antibiotics other than methicillin occurred in a number of countries at approximately the same time. Neomycin-resistant and gentamicin-resistant strains emerged in several countries -10 years after the introduction of these drugs [15, 16] . It seemed unlikely that intercountry and intercontinental spread of strains accounted entirely for this phenomenon. A decline in the frequency of multiply resistant strains of S. aureus, including MRSA, occurred in European countries in the 1970s. The reason, although not clear, may have been a reduction in the use of tetracycline, and possibly, steptomycin [17, 18] . The use of gentamicin increased, but this was an unlikely cause of the decreased frequency of the multiply resistant strains, even though gentamicin resistance was often present in strains isolated in the second wave of MRSA [19] . During this earlier period, there were improvements in infection control and antibiotic use, and these factors may also have played a role in the decline of the multiply resistant organisms. A reduction in the number of specific transmissible phage types is a more likely explanation, but laboratory evidence is lacking.
The Second Wave of MRSA
The "new" MRSA strains emerged mainly in the late 1970s and early 1980s in Australia [20] , the Irish Republic [21] , and the United States [22] , but reports of hospital and interhospital outbreaks in other countries were increasing. Although outbreaks were rarely reported during the intervening period between the two waves, sporadic MRSA isolates were still recovered in the United Kingdom and other countries, and the number of sporadic isolates increased in the 1980s. However, it was not until 1981 that an epidemic strain emerged in London hospitals and spread to southeastern England [23] . This strain (EMRSA 1) was followed by a series of other epidemic strains, of which at least 16 have been described [24, 25] (table 3) . EMRSA 1 is similar to the Australian epidemic strain.
A considerable reduction in the frequency of MRSA was observed between 1970 and 1980 at a large general hospital in Birmingham, England (table 2) . No large outbreaks occurred between 1980 and 1991, but epidemic MRSA (EMRSA 15) reappeared in 1991 (figure 1). Preventative measures including the use of an isolation unit, which were previously successful, were less effective in controlling this outbreak, and it continues. The introduction of colonized patients from the community who had acquired the organism during a previous admission to this hospital or to another hospital increased the difficulty in controlling the outbreak.
The United States National Nosocomial Infections Study showed that the frequency of MRSA among 16,132 S. aureus isolates increased from 2.4% in 1975 to 29% in 1991 [26] . A survey in Italy of 1,927 strains of S. aureus showed that the frequency increased from 6% in 1981 to 26% in 1986 [27] . At a hospital in Shanghai, the frequency of MRSA increased from 40% in 1987 to 67% in 1992 [28] .
A similar increase in the recovery of MRSA isolates has occurred in many countries in Europe (e.g., Greece [29] , France [30], and Germany [31] ). An epidemic similar to that of EMRSA 1 in the United Kingdom has spread in Spain [32] . A European study in which 200 isolates of S. aureus from 43 hospitals in 10 countries were screened showed that the frequency of MRSA isolates ranged from < 1% to 30% [33] . Isolation rates tended to be highest in southern Europe (30%). [24, 25] . Bac = bacitracin; Cpfx = ciprofloxacin; Em = erythromycin; Fus = fusidic acid; Gm = gentamicin; Km = Kanamycin; Pen = penicillin; Rif = rifampin; RTD = routine test dilution; Tet = tetracycline. Resistance to antibiotics listed in parentheses was variable.
Spread of MRSA has occurred in many other regions [34] including the Middle East, Africa, Russia, South America, and the Far East. In some countries, MRSA isolates seem to have reached an equilibrium or are even decreasing in frequency [35] .
The increased incidence of infection or colonization with MRSA has not occurred in all countries. For example, in Denmark only 0.2% of S. aureus isolates recovered since 1984 have been MRSA [36] . The reason remains unclear. A possible explanation for the low number of MRSA isolates in some countries could be the rapid detection of patients, particularly those from other countries, who are infected with MRSA and the prompt isolation of such patients. The restricted use of antibiotics, especially thirdgeneration cephalosporins, is another possible reason. Antibiotic use appears to be lower in Denmark and Sweden than in the countries where MRSA is a problem, but further evidence as to the role of specific antibiotics in the selection of MRSA is required.
In Holland, the spread of MRSA has also effectively been avoided or reduced. Screening and obtaining information on patients infected with MSRA who are transferred from other countries would seem to be effective [37] . The incidence of MRSA in Holland from 1991 to 1992 was only 0.54% among 27,127 S. aureus isolates. In Australia, screening of patients or hospital staff entering western Australia from eastern Australia and other countries, prompt isolation of such persons, and application of preventative measures have been effective [38] , although more MRSA isolates are now being detected [39] . However, in many hospitals around the world, surveillance and control measures that have hitherto been effective have failed to control the spread of epidemic strains.
Transfer of MRSA between countries, with occasional subsequent outbreaks, have often been reported. In Denmark, 44 patients infected with MRSA were identified between 1986 and 1988, and 48% of these patients were from other countries [36] . Between 1989 and 1992, 491 patients with MRSA were identified in Holland; 116 different MRSA phage types were recovered from patients who were from 26 different countries [37] . A strain of MRSA (phage type 77) was introduced into a bum unit in Sweden by a patient from Zambia with a bum that covered 45% of the patient's body. Forty-seven of 233 patients in one unit in Sweden were colonized or infected, and MRSA spread to another bum unit in which 15 of 220 patients were colonized or infected. However, spread did not occur to other wards [40] .
A patient from Baghdad who had major traumatic injuries was admitted to a hospital in Dublin in 1985. He was colonized with two strains of MRSA that spread in two hospitals over several years [41] . Nevertheless, importation alone is unlikely to account for the widespread dissemination of MRSA over a relatively short period. Carriers in the community who have had no previous contact with hospitals are rare; however, outbreaks due to readmission to the same or another hospital of patients who acquired the strain from a previous hospital stay are being reported more frequently. Outbreaks among drug addicts have also been reported [42] .
The "new" MRSA isolates are usually resistant to several antibiotics, which often include gentamicin, trimethoprim, and more recently, ciprofloxacin and mupirocin. The strains are often nontypable with the conventional phages but have been typed with new phages (e.g., phage types 88A, 90, 83C, 932 [24] ) (table 3). The typable strains are mainly group III and commonly include phages 84, 85, and 83A. The increase in nontypability of phages has led to the use of molecular methods for typing [43] [44] [45] [46] [47] . These methods have confirmed genetic similarities and differences between strains in the same hospital or country. Nevertheless, typing with a wide range of phages is still useful for monitoring the spread of strains within and between hospitals.
Genetic Changes and the Spread of MRSA
The genetic basis of antimicrobial resistance in S. aureus has been well reviewed by Lyon and Skurray [48] . The gene responsible for intrinsic methicillin resistance, MecA, encodes the penicillin-binding protein PBP2a [49] . This gene was present in the earliest isolates of MRSA, is distributed worldwide, and is probably transposable [50] . An evolutionary tree has been proposed, with diversification from a single starting point that possibly arose from the fusion of staphylococcal /3-lactamase and an ancestral protein of PBP2a acquired from another organism (e.g., Escherichia coli). Multiple episodes of horizontal transfer and recombination may have contributed to the spread of resistance determinants in natural populations [51] .
A single multilocus enzyme genotype has been proposed for the strains recovered in the 1960s from the United Kingdom, Denmark, Switzerland, Uganda, and Cairo, and there is evidence that the "old" strains differ from the new strains in the United Kingdom and Australia; these new strains probably differ from strains in the United States [51, 52, 53] . Coagulase-negative staphylococci are frequently resistant to methicillin, and in vitro transfer of methicillin resistance to S. aureus has been reported, but the clinical relevance is unknown.
Although there is evidence of a single genetic starting point or ancestral clone for MRSA, it is unlikely that this initial genetic change occurred in any one country and then spread to many other countries over the relatively short period involved. It seems more likely that small numbers of naturally methicillin-resistant strains of S. aureus emerged in many countries before the introduction of methicillin. Some spread may have occurred between the transposons of the organisms, and new clones have emerged, but crossinfection of organisms in colonized or infected patients is the main mode of spread.
Discussion
It is not known why the initial spread of MRSA occurred mainly in Europe. Although MRSA was present in the United States at the time, the isolates did not cause major outbreaks for another 10-15 years. It is possible that the strains in the United States did not possess the high transmissibility of the early European strains recovered in the 1970s. The reason for the disappearance of epidemic strains from the United Kingdom and Scandinavia also remains uncertain.
The existing high level of colonization and infection of patients around the world is now difficult to control, and extensive control measures may not be cost effective, particularly if clinical infections are not a problem [54] . Isolation of resistant strains may decline in frequency as did the old MRSA strains in the absence of any special control measures, but there is little evidence that this is occurring in most countries. Measures to prevent spread should therefore be applied, depending on resources (e.g., rapid detection, hand washing by staff, isolation of infected or colonized patients, and eradication with use of antiseptics). Screening and isolation of patients or staff transferred from affected units or other countries with a known MRSA problem are important preventative measures [55] [56] [57] .
If resources are limited or a strain has become endemic in the wards of a hospital, control measures should be prioritized-e.g., methods for eradication of the organisms in highrisk units and general hygienic methods in long-term care establishments-but every effort should be made to prevent an epidemic strain from spreading in a hospital where it was previously absent [58] .
Excessive use of antibiotics (not necessarily the penicillinase-resistant penicillins) has played a major role in the increasing incidence of resistance, although it is difficult to establish the role of any particular antibiotic in the increased frequency of MRSA. The third-generation cephalosporins, and more recently, the quinolones may have had a selective influence, and an increasing number of strains are resistant to mupirocin [59, 60] .
The control of antibiotic use, in addition to measures for reducing nosocomial infections, is the best approach despite its present failure in many countries. This approach requires encouragement and resources from governments and health authorities as well as the introduction of educational programs. In addition, clinicians must be persuaded that MRSA is a major problem, even if they are seeing few patients with clinical infections. More studies are required to determine the reasons for the decline or emergence of resistant S. aureus populations, and on the mechanisms of colonization and transmissibility of MRSA.
